Scientists pave the way for saliva test for Alzheimer's disease

University of Alberta scientists have identified three biomarkers for detecting mild cognitive impairment and Alzheimer's disease in saliva samples. The research has promising results for application in a clinical setting. The research team combines expertise in metabolomics from Liang Li, professor in the Department of Chemistry, and neurodegenerative disorders from Roger Dixon, professor in the Department of Psychology.

"All projections point to an impending and staggering global impact of neurodegenerative disease and dementia," said Dixon of the critical importance of this research.

Li and Dixon examined saliva samples from three sets of patients, those with Alzheimer's disease, those with mild cognitive impairment, and those with normal cognition. Using a powerful mass spectrometer, the pair examined more than 6,000 metabolites--compounds that are part of our body's metabolic processes--to identify any changes or signatures between groups.

"In this analysis, we found three metabolites that can be used to differentiate between these three groups," said Li. "This is preliminary work, because we've used a very small sample size. But the results are very promising. If we can use a larger set of samples, we can validate our findings and develop a saliva test of Alzheimer's disease."

A saliva test would prove useful in clinical settings for its ease and non-invasive nature. It also has the potential to detect neurodegenerative diseases earlier on, allowing for early intervention.

"So far, no disease-altering interventions for Alzheimer's disease have been successful," explained Dixon. "For this reason, researchers are aiming to discover the earliest signals of the disease so that prevention protocols can be implemented."

Another added benefit of identifying these biomarkers is the ability to conduct efficacy testing for treatments. "Using the biomarkers, we can also do testing to see what types of treatments are most effective in treating Alzheimer's disease--from diet to physical activity to pharmaceuticals," added Li.

Sapkota Shraddha, Huan Tao, Tran Tran, Zheng Jiamin, Camicioli Richard, Li Liang, Dixon Roger A.
Alzheimer's Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers.
Front. Aging Neurosci. doi: 10.3389/fnagi.2018.00296.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...